Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cyclophosphamide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    790 result(s) found for: Cyclophosphamide. Displaying page 6 of 40.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2004-001199-37 Sponsor Protocol Number: GOTEL-2003 Start Date*: 2004-08-19
    Sponsor Name:(GOTEL) Grupo Oncológico para el tratamiento y estudio de los linfomas
    Full Title: A Phase II, Single Arm, Open label Study of Cyclophosphamide, Vincristine, Liposomal Doxorubicine (Myocet™) and Prednisone plus Rituximab in Fortnightly Regimen (R-COMP-14), as First Line of thera...
    Medical condition: Dose-dense modified R-CHOP regimen (R-COMP) in patients with aggressive NHL.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017328-25 Sponsor Protocol Number: PACOVAR Start Date*: 2010-10-18
    Sponsor Name:University Hospital Heidelberg
    Full Title: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer
    Medical condition: This study is a prospective open-label, non-randomized multicenter phase I/II trial in order to determine overall response rate of patients with platinum-resistant or refractory recurrent, pretreat...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003723-21 Sponsor Protocol Number: BSMO-2014-01 Start Date*: 2015-05-27
    Sponsor Name:Belgian Society of Medical Oncology
    Full Title: A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple ne...
    Medical condition: Stage II and III triple negative breast cancer patients suitable for preoperative chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005803-33 Sponsor Protocol Number: TH06-001 Start Date*: 2007-01-18
    Sponsor Name:THERABEL LUCIEN PHARMA
    Full Title: ÉTUDE PILOTE OBSERVATIONNELLE CHEZ DES PATIENTES SOUFFRANT D’UN CANCER DU SEIN ET RECEVANT UNE CHIMIOTHÉRAPIE ÉMÉTISANTE TRAITÉES PAR UNE DOSE UNIQUE DE ALOXI® (PALONOSÉTRON) 0,25 MG ASSOCIÉE À UNE...
    Medical condition: The prevention of acute or delayed Chemotherapy-Induced Nausea and Vomiting (CINV) by the combination of palonosetron 250 microgrammes and methylprednisolone 80 mg in patients receiving a first adm...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10056989 Nausea post chemotherapy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016453-17 Sponsor Protocol Number: IEO S504/409 Start Date*: 2009-12-17
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Phase II study of preoperative bevacizumab plus weekly paclitaxel, carboplatin and metronomic cyclophosphamide � trastuzumab and endocrine therapy for inflammatory breast cancer
    Medical condition: Inflammatory breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021980 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003920-30 Sponsor Protocol Number: CHARLY Start Date*: 2016-09-20
    Sponsor Name:University Hospital Heidelberg
    Full Title: Phase-II study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma
    Medical condition: Myeloablative haplo-identical stem cell transplantation for poor risk non-hodgkin lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001690-62 Sponsor Protocol Number: HE2016 Start Date*: 2014-09-16
    Sponsor Name:University of Birmingham
    Full Title: A randomised phase II clinical trial of conditioning cyclophosphamide and chemoembolisation with or without vaccination with dendritic cells pulsed with HepG2 lysate ex vivo in patients with Hepato...
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-010998-20 Sponsor Protocol Number: HM09/8848 Start Date*: 2009-06-25
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: Attenuated dose Rituximab with ChemoTherapy In CLL: A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) to compare fludarabine, cyclophosphamide ...
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-006342-25 Sponsor Protocol Number: HM08 / 8625 Start Date*: 2009-02-09
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or withou...
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-021557-40 Sponsor Protocol Number: MM-Rel Start Date*: 2011-03-03
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A phase III trial comparing bortezomib, cyclophosphamide and dexamethasone versus lenalinomide cyclophosphamide and dexamethasone in patients with multiple myeloma at first relapse
    Medical condition: Multiple mieloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003993-85 Sponsor Protocol Number: CETRA Start Date*: 2006-11-10
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: Phase II Study of neoadjuvant therapy with trastuzumab plus docetaxel followed by trastuzumab plus pegylated liposomal doxorubicin and cyclophosphamide in human ErbB-2-positive operable or locally ...
    Medical condition: Operable breast cancer patients or locally advanced breast cancer patients (stage II-III), with HER2 overexpression or gene amplification
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023577-20 Sponsor Protocol Number: REPEAT Start Date*: 2011-06-24
    Sponsor Name:VU University Medical Center
    Full Title: Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT): A phase 1 and phase 2 study of lenalidomide (Revlimid) in combination with cyclophosphamide (endoxan) and predniso...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005666-12 Sponsor Protocol Number: IMA910-101 Start Date*: 2008-04-15
    Sponsor Name:immatics biotechnologies GmbH
    Full Title: An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyc...
    Medical condition: Adult HLA-A*02-positive patients who have been diagnosed with unresectable, locally advanced and/or metastatic colorectal cancer before first-line chemotherapy. Patients must have completed a 12 we...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) GB (Completed) LV (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001065-17 Sponsor Protocol Number: GEL-R-COMP-2013 Start Date*: 2013-08-01
    Sponsor Name:Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO)
    Full Title: Phase II, randomised, multicentre study with two treatment arms (R-COMP versus R-CHOP) in newly diagnosed elderly patients (?60 years) with non-localised diffuse large B-cell lymphoma (DLBCL)/folli...
    Medical condition: Non-localised diffuse large B-cell lymphoma/Follicular lymphoma grade IIIb
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000981-46 Sponsor Protocol Number: IC2015-13 Start Date*: Information not available in EudraCT
    Sponsor Name:INSTITUT CURIE
    Full Title: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years -
    Medical condition: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055101 Bone cancer metastatic PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001117-17 Sponsor Protocol Number: GEICAM/2004-05 Start Date*: 2005-11-30
    Sponsor Name:GEICAM (GRUPO ESPAÑOL DE INVESTIGACION EN CANCER DE MAMA)
    Full Title: PHASE IV.II, CLINICAL TRIAL, WITH THE COMBINATION OF PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX), CYCLOPHOSPHAMIDE AND TRASTUZUMAB (HERCEPTIN) IN PATIENTS WITH METASTATIC BREAST CANCER WITH OVEREXPRES...
    Medical condition: PATIENTS WITH METASTATIC BREAST CANCER AND OVEREXPERSSION OF HER2NEU
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001320-36 Sponsor Protocol Number: HM12/10191 Start Date*: 2012-08-28
    Sponsor Name:University of Leeds
    Full Title: A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma.
    Medical condition: multiple myeloma at the first relaspe of primary refractory disease stage
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000427-42 Sponsor Protocol Number: LT 2005 XX Start Date*: 2005-04-15
    Sponsor Name:UK Children’s Cancer Study Group
    Full Title: SIOPEL 5 (HCC-1) trial on the hepatocellular carcinoma family of tumours in children/adolescents and young adults
    Medical condition: Hepatocellular carcinoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002670-12 Sponsor Protocol Number: HM16/235 Start Date*: 2017-03-21
    Sponsor Name:Univeristy of Leeds
    Full Title: MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agentsoptimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia.
    Medical condition: Newly diagnosed high risk multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-002197-34 Sponsor Protocol Number: 04/Q1104/27 Start Date*: 2004-12-14
    Sponsor Name:University College London
    Full Title: A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed d...
    Medical condition: Newly diagnosed diffuse large B cell non-Hodgkin's lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:22:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA